Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis

2016 ◽  
Vol 35 (4) ◽  
pp. 810-813 ◽  
Author(s):  
Uday Deotare ◽  
Marwan Shaheen ◽  
Joseph M. Brandwein ◽  
Bethany Pitcher ◽  
Suzanne Kamel-Reid ◽  
...  
2020 ◽  
Vol 42 (6) ◽  
pp. e423-e427
Author(s):  
Neelum Mansoor ◽  
Naeem Jabbar ◽  
Uzma Arshad ◽  
Sidra Maqsood ◽  
Muhammad A. Habib ◽  
...  

2017 ◽  
Vol 92 (9) ◽  
pp. 845-850 ◽  
Author(s):  
Brittany Knick Ragon ◽  
Naval Daver ◽  
Guillermo Garcia-Manero ◽  
Farhad Ravandi ◽  
Jorge Cortes ◽  
...  

2014 ◽  
Vol 38 (7) ◽  
pp. 773-780 ◽  
Author(s):  
Andrew M. Brunner ◽  
Traci M. Blonquist ◽  
Hossein Sadrzadeh ◽  
Ashley M. Perry ◽  
Eyal C. Attar ◽  
...  

2022 ◽  
Vol 11 ◽  
Author(s):  
Min Yang ◽  
Bide Zhao ◽  
Jinghan Wang ◽  
Yi Zhang ◽  
Chao Hu ◽  
...  

Core Binding Factor (CBF)-AML is one of the most common somatic mutations in acute myeloid leukemia (AML). t(8;21)/AML1-ETO-positive acute myeloid leukemia accounts for 5-10% of all AMLs. In this study, we consecutively included 254 AML1-ETO patients diagnosed and treated at our institute from December 2009 to March 2020, and evaluated molecular mutations by 185-gene NGS platform to explore genetic co-occurrences with clinical outcomes. Our results showed that high KIT VAF(≥15%) correlated with shortened overall survival compared to other cases with no KIT mutation (3-year OS rate 26.6% vs 59.0% vs 69.6%, HR 1.50, 95%CI 0.78-2.89, P=0.0005). However, no difference was found in patients’ OS whether they have KIT mutation in two or three sites. Additionally, we constructed a risk model by combining clinical and molecular factors; this model was validated in other independent cohorts. In summary, our study showed that c-kit other than any other mutations would influence the OS in AML1-ETO patients. A proposed predictor combining both clinical and genetic factors is applicable to prognostic prediction in AML1-ETO patients.


Leukemia ◽  
2018 ◽  
Vol 32 (7) ◽  
pp. 1621-1630 ◽  
Author(s):  
Peter Paschka ◽  
Richard F Schlenk ◽  
Daniela Weber ◽  
Axel Benner ◽  
Lars Bullinger ◽  
...  

2020 ◽  
Vol 20 ◽  
pp. S186
Author(s):  
Hassan Awada ◽  
Carmelo Gurnari ◽  
Manja Meggendorfer ◽  
Arda Durmaz ◽  
Teodora Kuzmanovic ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document